Slide 1: Slide 1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21 of the Securities
Slide 3: Clinical-Stage Innovative Pipeline
CLINICAL-STAGE Innovative pipeline: BIO PHARMACEUTI CAL First-in-class oral drugs with unique COMPANY (NASDAQ: IMUX) eae perottestinal ciceases Dedicated to improving the lives of patients with chronic inflammatory and autoimmune diseases F A Experienced leadership team: Successfully developed and c
Slide 4: Leadership Team
Leadership Team Company is Led by an Experienced Management Team Daniel Vitt, Jason Tardio, Andreas Muehler, PhD MBA MD, MBA Chief Executive President & Chief Chief Medical Officer Operating Officer Officer Hella Kohlhof, PhD Chief Scientific Officer Patrick Walsh Chief Business Officer Glenn Whaley
Slide 5: Advanced Clinical Pipeline
Advanced Clinical Pipeline Well Differentiated Programs in Various Phases of Clinical Development Program Preclinical Phase 1 Phase 2 Phase 3 Key Program Updates Y Phase 2 EMPHASIS trial in relapsing-remitting MS successfully completed RE-1 and ENSURE-2 Trials ¥ Interim futility analysis of ENSURE p
Slide 6: Slide 6
Slide 7: Vidofludimus Calcium Has the Potential to Transform the Oral MS DMT Market
Vidofludimus Calcium Has the Potential to Transform the Oral Multiple Sclerosis DMT Market Designed to Combine the Best of Two Worlds: Neuroprotection and Relapse Prevention First-in-class, dual mode of action approach designed to address the full spectrum of disease: = Nurr1 activation provides dir
Slide 8: Multiple Sclerosis is a Lifelong Neurodegenerative Disease
Multiple Sclerosis is a Lifelong Neurodegenerative Disease Lifelong Disease Requiring Decades of Therapy it Therapeutic Goal: Increase Independence ~2.9 million people affected worldwide! ~1 million people affected in USI] Often diagnosed in younger adults (3:1 women:men) = Key unmet need: preventio
Slide 9: The Unmet Medical Needs in Multiple Sclerosis
The Unmet Medical Needs in Multiple Sclerosis Despite Being on Efficient Relapse-Targeting hs Therapies, Majority of Patients Still Experiences Disability Worsening@! G Goals for New © Multiple Sclerosis Treatments 87% of DMT-treated patients report disease progression in last 5 years 100% 5 50% S 0
Slide 10: Underlying Invisible Disability Accumulation Contributes to Disability Progression
Underlying “Invisible Disability Accumulation” Contributes to Disability Progression Over Time Requiring a Dual Mode of Action Approach These observations challenge the = dichotomy between relapsing and Nome progressive disease, supporting a Cop one stage disorder model of MS, [ Nurra where all pati
Slide 11: There Are Three Distinct MS Indications
There Are Three Distinct MS Indications The Different Indications Have Different Paths and Drivers of the Disability Progression Relapsing MS = Indudes relapsing-remitting MS and active secondary progressive MS = Relapses and MRI lesions dominate clinical course, disability progression already prese
Slide 12: A Large and Growing Global Market Where Multiple Blockbusters Coexist
A Large and Growing Global Market Where Multiple Blockbusters Coexist Many brands are generating in excess of $1 billion in global annual sales in 202311 Ocrevus® $7.2 billion Kesimpta® $2.2 billion Tysabri® $1.9 billion Tecfidera® & Vumerity® $1.6 billion Avonex® & Plegridy® $1.1 billion Mavenclad®
Slide 13: Oral DMTs Will Continue to Play a Big Role as Important Treatment Options
Oral DMTs Will Continue to Play a Big Role as Important Treatment Options IS I) While the anti-CD20 class of therapies continues to grow, the oral class still captures over 1/3 of the global market Global Market Share by Drug Class 2022 vs. 2032/41 6 = Data supports that 42% of patients prefer oral
Slide 14: Multiple MS Patient Segments Could Benefit from Vidofludimus Calcium
Multiple MS Patient Segments Could Benefit from Vidofludimus Calcium Older patients where . = : O Newly diagnosed patients immunosuppression is a concern Patients switching therapies due to disability Untreated patients worsening Patients switchin < . 5 3 Patients with progressive ~z therapies due t
Slide 15: Vidofludimus Calcium: Derisked Near-Term Opportunity with $2-6 Billion Peak Potential
Vidofludimus Calcium: Derisked Near-Term Opportunity with $2-6 Billion Peak Potential RMS nrsPMS PPMS Indication Phase 3 Phase 2 Phase 2 Status Clinical 76% reduction in 20.1% reduction in serum NfL compared 18.8% reduction in serum NfL compared eis new Gd+ lesions (Phase 2) to placebo in nrSPMS pat
Slide 16: Slide 16
Slide 17: Vidofludimus Calcium Addresses Smoldering Neurodegeneration
Vidofludimus Calcium Addresses Smoldering Neurodegeneration SS First-in-Class Nurr1 Activator, Targeting Improvement of Physical and Mental Ability of Multiple Sclerosis Patients Nurri Activator = Direct and indirect neuroprotective effects = Involved in protecting relevant neurons from cell death =
Slide 18: Nurr1 Is a Nuclear Receptor Involved in Neuroprotection
Nurr1 Is a Nuclear Receptor Involved in Neuroprotection Nurr1 is expressed in different cells relevant for neuroprotection microglia astrocyte neuron AAW AA Nurr1 activation prevents microglia/ Nurr1 activation mediates neuronal survival astrocyte-driven neurotoxicity in the brain Nurr1 activation i
Slide 19: MS Progression/Activity is Naturally Lowered During Pregnancy
MS Progression/Activity is Naturally Lowered During Pregnancy Linked to Nurr1 Upregulation Women with MS experience 347 transcript differentially expressed in RRMS a substantial reduction of peripheral blood compared to healthy control 8 genes (e.g., Nurr1) iy disease activity during 0.0 17 6 revert
Slide 20: Further Role of Nurr1 in MS
Further Role of Nurr1 in MS: Nurr1 is Downregulated in MS Patients Nurr1 Is a Nuclear Receptor Involved in Neuroprotection Nurr1 activation delays the onset of the MS and counteracts inflammation in EAE animal models of Ms."] In untreated patients with relapsing-remitting MS, Nurr1 was significantly
Slide 21: Vidofludimus Calcium Activates Nurr1, Postulated to Increase Neuronal Survival
Vidofludimus Calcium Activates Nurr1, Postulated to Increase Neuronal Survival Hy rene Gene Expression yong Improves Neuronal Nurr1 Binding Regulation Survival Nurr1 is a transcription factor binding Vidofludimus calcium induces a > 2-fold induction Vidofludimus calcium improves neuronal survival to
Slide 22: Vidofludimus Calcium: General Effects on MS Disease Processes
Vidofludimus Calcium: General Effects on MS Disease Processes Improving the survival of neurons in a neurotoxic environment Nurr1 Activation Reducing the activation of microglia (which are a source of a neurotoxic environment) Targeting metabolically active immune cells involved in MS DHODH Inhi in
Slide 23: Vidofludimus Calcium: Clinical Trials Overview in Multiple Sclerosis
Vidofludimus Calcium: Clinical Trials Overview in Multiple Sclerosis (MS) ENSURE-2 | RELAPSING MS ee Phase 3 Actively recruiting, n=1050 patients planned Or aOrr (expected) ENSURE-1 | RELAPSING MS is et Phase 3 Actively recruiting, n=1050 patients planned OMIPEMOL (expected) April 2025 Top-Line Data
Slide 24: Slide 24
Slide 25: Vidofludimus Calcium Could be the First Treatment Option for Relapsing MS
Vidofludimus Calcium Could be the First Treatment Option for Relapsing MS Fulfilling the Current Unmet Needs of Patients Gi Goals for New Relapsing Multiple Sclerosis Treatments = Developing a new therapy offering: — Neuroprotection and effect on progression independent of relapse activity (PIRA) —
Slide 26: EMPhASIS: Completed Phase 2 Trial in Relapsing-Remitting MS
EMPhASIS: Completed Phase 2 Trial in Relapsing-Remitting MS NCT03846219 Viet Trial Met Key LG Efficacy and Safety Endpoints = Randomized 268 patients in 36 centers across four fe Coordinating Investigator European countries = Vidofludimus calcium showed strong activity in relapsing- remitting MS pop
Slide 27: EMPhASIS: Strong Reduction of MRI Lesion Activity
EMPhASIS: Strong Reduction of MRI Lesion Activity Primary Endpoint Hit With High Statistical Significance, Pooled Cohorts 1 & 2 Reduction in Cumulative CUA Lesions up to Week 24 Reduction in Gd+ Lesions up to Week 24 o 0 7 0 5 13% 8 é -10 4s -10 -20 4 -20 5 30 35 30 4 -40 3 -40 -50 25 -50 3 “71% -60
Slide 28: EMPhASIS: Reduction of Serum NfL Concentrations Observed
EMPhASIS: Reduction of Serum NfL Concentrations Observed Versus Placebo After 24 Weeks, Pooled Cohorts 1 & 2 50% -50% 10 mg IMU-838 Displayed are median valuesof cfferances betvaen percentage change of serum neurofilament light chain concentration (Hodges'.zhmann estimation) trastment vs placebo Dat
Slide 29: EMPhASIS: Reduced Confirmed Disability Worsening Events
EMPhASIS: Reduced Confirmed Disability Worsening Events End of 24-Week Blinded Treatment Period CDW Events at the End of the 24-Week Blinded Treatment Period 4.0% 3.7% 3.7% 3.5% 3.0% Data confirms a signal in 2.5% preventing 12-week and 24-week 2 1.6% 1.6% confirmed disability worsening aaa events a
Slide 30: EMPhASIS: Low Rates of Confirmed Disability Worsening Events
EMPhASIS: Low Rates of Confirmed Disability Worsening Events Interim Analysis Open-Label Extension Period 12-Week CDW Events Proportion of patients free of 12-week confirmed disability worsening after 1 and 2 years of open-label extension vidofludimus calcium treatment 97.2% 94.2% Data confirms that
Slide 31: EMPhASIS: 12-Week Confirmed Disease Worsening After 2 Years
EMPhASIS: 12-Week Confirmed Disease Worsening After 2 Years Interim Analysis Open-Label Extension Period Compared to Select Historical Trials RRMS patients with 12-week (3-months) confirmed disability worsening after 2 Years (96 Weeks) (% of patients at risk) 20% 15% 15.0% KM estimates 13.6% i 12.4%
Slide 32: Vidofludimus Calcium: Unrivaled Safety and Tolerability Profile
Vidofludimus Calcium: Unrivaled Safety and Tolerability Profile Observed in Multiple Clinical Trials = Safety profile similar to placebo: no general safety signals observed in clinical trials so far = No increased rates of diarrhea, neutropenia, or alopecia = No increased rates of infections and inf
Slide 33: EMPhASIS: Vidofludimus Calcium Well-Tolerated With Adverse Events Similar to Placebo
EMPhASIS: Vidofludimus Calcium Well-Tolerated With Adverse Events Similar to Placebo Vidofludimus Vidofludimus Safety & Tolerability Endpoints Placebo Calcium 30mg Calcium 45mg ‘Any treatment-emergent adverse event 44% 45% 41% Treatment-emergent adverse events occurring in >5% of total patients by p
Slide 34: EMPhASIS: Patients Feel Well-Treated With Vidofludimus Calcium
EMPhASIS: Patients Feel Well-Treated With Vidofludimus Calcium Reflected in Low Discontinuation Rates for Vidofludimus Calcium-Treated RRMS Patients, Considerably Lower Than Placebo* Vidofludimus Glatiramer ae eats Aubagio® 1 Tecfidera® #1 Gilenya® (4) Zeposia® (51 Administration Oral Injectable Ora
Slide 35: ENSURE: Ongoing Pivotal Phase 3 Trials in Relapsing MS
ENSURE: Ongoing Pivotal Phase 3 Trials in Relapsing MS NCT05134441 & NCT05201638 x Coordinating Investigator Two Multicenter, Randomized, Double-Blind Phase 3 Trials Robert J. Fox, M.D. Cleveland Clinic Included Patient Population: Approximately 1,050 patients in each trial More than 100 sites in th
Slide 36: ENSURE: Positive Outcome of Interim Futility Analysis
ENSURE: 36 | © immunic, inc. | Jan/13/2025 Positive Outcome of Interim Futility Analysis Unblinded Independent Data Monitoring Committee (IDMC) confirmed predetermined futility criteria have not been met IDMC recommended continuing trial without changes, including no need for a potential upsizing Ba
Slide 37: Slide 37
Slide 38: CALLIPER: Designed to Lay the Foundation for a Potential Confirmatory Phase 3 Program
38 | © immunic, inc. | Jan/13/2025 CALLIPER: Designed to Lay the Foundation for a Potential Confirmatory Phase 3 Program in Progressive Multiple Sclerosis Phase 2 trial trial evaluating the efficacy, safety and tolerability of 45 mg vidofludimus calcium Ina broad set of PMS patient subtypes: primary
Slide 39: CALLIPER: Patients with PMS Remain Underserved With Limited to No Treatment Options
CALLIPER: Patients with PMS, Particularly Non-Active Disease, Remain Underserved With Limited to No Treatment Options Neurodegenerative pathological mechanisms in the brain are believed to form the dominant origin of PMS requiring drugs with neuroprotective properties to be effectivel®l Although ove
Slide 40: Phase 2 EMPhASIS Trial Outcomes Drove Excitement for PMS Treatment Potential
Phase 2 EMPhASIS Trial Outcomes Drove Excitement for PMS Treatment Potential In the phase 2 EMPhASIS trial in RRMS, the following observations provided the rationale for testing vidofludimus calcium asa possible neuroprotective therapy in PMS: Dose-dependent reduction of the biomarker serum neurofil
Slide 41: CALLIPER: Ongoing Phase 2 Clinical Trial in Progressive MS
CALLIPER: Ongoing Phase 2 Clinical Trial in Progressive MS NCT05054140 Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial Main Treatment Per Screening Period Maximum 120 Weel = 467 patients enrolled at more than 70 sites in North America, Western, Visits every 12 weeks ee» Centr
Slide 42: CALLIPER: Patient Demographics and Baseline Characteristics
CALLIPER: Patient Demographics and Baseline Characteristics Total Study Population of 467 Enrolled Patients Progressive Disease Subtypes Baseline Characteristics Baseline Patient Characteristics Total (N=467) N=37 79% ‘Age [years], median (min-max) 51.0 (21-65) Gender (n and % female) 302 (64.7%) pr
Slide 43: PPMS Patients Treated with Ocrelizumab That Achieved Lower Levels of NfL Had Lower Risk
PPMS Patients Treated with Ocrelizumab That Achieved Lower Levels of NfL Had a Lower Risk for Future Disability Ocrelizumab ORATORIO Study in ORATORIO (OCR arm) 100% pa:0cR > ToLE: ocr 5 PPMS as Historical Comparison Years” {Year| OLE basolne P=0.058 { P=0.019 = Blood NfL levels re-baselined at Week
Slide 44: CALLIPER Interim Data: Improvements in Serum NfL for Vidofludimus Calcium
CALLIPER Interim Data: Improvements in Serum NfL for Vidofludimus Calcium Consistent Throughout the Overall PMS Population and All Subtypes Mean Change to Week 24 as Compared to Placebo in % of Baseline 10% Overall PMS Population PPMS n-aSPMS- aSPMS N=102 (IMU-838) N=32 (IMU-838) N=62 (IMU-838) N=8
Slide 45: NfL Reduction Compares Favorably with Other MS Therapies
NfL Reduction Compares Favorably with Other MS Therapies CALLIPER Interim Data Compared to Select Historical Trials Vidofludimus Ocrelizumab Vidofludimus Siponimod Vidofludimus Siponimod PPMS PPMS n-aSPMS n-aSPMS.__ aSPMS aSPMS |. (CALLIPER) (ORATORIO) (CALLIPER) (EXPAND) (CALLIPER) (EXPAND) 10% N=3
Slide 46: Positive Interim Biomarker Data of Vidofludimus Calcium in Progressive MS
Positive Interim Biomarker Data of Vidofludimus Calcium in Progressive Multiple Sclerosis Biomarker evidence that vidofludimus calcium’s activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential Vidofludimus calcium aiming to
Slide 47: CALLIPER: Results Will Educate Potential Phase 3 Program in Progressive MS
A CALLIPER: Results Will Educate Potential Phase 3 Program in Progressive What Would Make CALLIPER a Positive Study? A medically meaningful and numerical reduction of disability, measured by EDSS+/EDSS, supported by biomarker, functional and MRI data DSS: Expanded Disablity Status Scale; MRE magneti
Slide 48: CALLIPER: Additional Outcome Measures
CALLIPER: Additional Outcome Measures Q MRI-Based Endpoints Biomarkers spe Functional Outcomes = Change in brain volume has traditionally been the most widely studied technical MRI endpoint in PMS populations = Newer MRI-based endpoints have shown promise in PMS (such as slowly expanding lesions, gr
Slide 49: Vidofludimus Calcium: DHODH Inhibition Provides Broad-Spectrum Antiviral Activity
Vidofludimus Calcium: DHODH Inhibition Provides Broad- Spectrum Antiviral Activity Against Different Pathogenic Viruses Inhibits Epstein-Barr Virus (EBV) Showed Dose-Dependent IN Decreased Number of Opportu- Replication and Reactivation Inhibition of EBV Reactivation nistic SARS-CoV-2 Infections By
Slide 50: Several Layers of Patents Protecting Vidofludimus Calcium
Several Layers of Patents Protecting Vidofludimus Calcium Eight Independent Patent Families Protecting Vidofludimus Calcium Calcium salt New polymorph and = IP for superior calcium salt and specific polymorph of the drug product specific salt/hydrate _ . . , and foarulation — Additional patent direc
Slide 51: Phase 3 Pipeline of Oral DMTs in Both RMS and PMS
Phase 3 Pipeline of Oral DMTs in Both RMS and PMS: Vidofludimus Calcium Is the Only Non-BTKi Nurr1 Activator / DHODH Inhibitor ATCT DCCL RELAPSING MS (ENSURE-1 & ENSURE-2) Phase 3 & Phase 2 Completion expected 2026 Immunic PROGRESSIVE MS (CALLIPER) THERAPEUTICS Data expected April 2025, BTK Inhibito
Slide 52: Vidofludimus Calcium in Multiple Sclerosis: Path Towards Potential Regulatory Approvals
Vidofludimus Calcium in Multiple Sclerosis Consistent and Differentiated Results to Towards Potential Regulatory Approvals EMPhASIS: Positive phase 2 RRMS data demonstrating statistically significant effect on lesion control and relapse prevention, with clear impact on serum NfL Aug 2020 Nov 2022 EM
Slide 53: Slide 53
Slide 54: IMU-856 Could Be the Perfect New Solution for Treating Gastrointestinal Disorders
IMU-856 Could Be the Perfect New Solution for Treating Gastrointestinal Disorders Without Harming the Immune System 54 | © immunic, inc, | Jan/13, = Innovative oral therapeutic approach applicable to a broad range of gastrointestinal disorders = Targets physiological intestinal epithelial regenerati
Slide 55: Once-Daily, Oral IMU-856 Aims to Regenerate the Gut Wall and Barrier Function
Once-Daily, Oral IMU-856 Aims to Regenerate the Gut Wall and Barrier Function by a New Innovative Targeted Mechanism Di d Gut Wall Healthy Gut Wall amaged Gut Wal jealthy Gut Wal IMU-856: = First-in-class modulator of Bowel lumen Bowel lumen irtuin 6 (SIRTS), t 6 antigens, microbiome, nutrients anti
Slide 56: IMU-856 Uniquely Suited for Potential Use in a Broad Spectrum of Serious GI Diseases
IMU-856 Uniquely Suited for Potential Use in a Broad Spectrum of Serious Gastrointestinal Diseases Demonstrated clinical proof-of-concept: Positive effects shown in a phase 1b clinical trial on gastrointestinal architecture and function applicable to multiple diseases with histological damage Celiac
Slide 57: SIRT6 Target Is Selectively Expressed in Gut Epithelial Cells
SIRT6 Target Is Selectively Expressed in Gut Epithelial Cells Highest mRNA Expressions in Paneth Cells, Enterocytes and Goblet Cells Small intestine a — Commensal bacteria = y= F 0. soy & /G y iy ay ut yin Gy Mp Wh Left: haps: /ony.protwinalas. orl / Right: Peterson, L, Arts D. Nat Rev Immunol 14, 1
Slide 58: IMU-856 Enhances the Natural Regenerative Process in the Gut
IMU-856 Enhances the Natural Regenerative Process in the Gut Gut wall renewal is a normal physiological process ‘ els Phyiereeice: Asymmetric cell division renews stem cells 1. Regeneration begins in the crypts, where and regenerates the gut wall intestinal stem cells are located 2. Stem cells under
Slide 59: Celiac Disease Currently Has No Adequate Treatment Options
Celiac Disease Currently Has No Adequate Treatment Options = Two million patients diagnosed with celiac disease in the ; _ or, . (1,21 10 mg of gluten is the total limit for all US; more than one million more undiagnosed!* foods combined for the entire day. = Most studies report between 24% and 47%!
Slide 60: First Proof-of-Concept for Gastrointestinal Disorders in Celiac Disease
First Proof-of-Concept for Gastrointestinal Disorders in Celiac Disease Celiac Disease is a Serious Life-Long Disease Celiac disease is a multifactorial, complex autoimmune disease caused by an immune reaction against a degradation product of gluten and is strongly associated with specific HLA oe gl
Slide 61: IMU-856 Demonstrated Clinical Proof-of-Concept in a Phase 1b Clinical Trial in Celiac Disease
IMU-856 Demonstrated Clinical Proof-of-Concept in a Phase 1b Clinical Trial in Celiac Disease Proof-of-Concept Study Designed as a Gluten Challenge Trial Flow Chart of Phase 1b Clinical Trial in Celiac Disease Day 1-28: Treatment IMU-8! = Celiac disease used as disease model to provide clinical proo
Slide 62: IMU-856 Showed Positive Effects in Four Main Dimensions of Clinical Outcome
IMU-856 Showed Positive Effects in Four Main Dimensions of Clinical Outcome in Celiac Disease Patients IMU-856 effectively protected against gluten-induced intestinal damage, as measured by villous Improve height t Patients’ Architecture Symptoms IMU-856 reduced/reversed gluten-induced symptoms repo
Slide 63: IMU-856 Protected Against Gluten-Induced Decrease in Villous Height
IMU-856 Protected Against Gluten-Induced Decrease in Villous Height as Compared to Placebo Absolute change in villous height (um) between Baseline and Day 29 Day 1-28: Treatment IMU-856/placebo o Day 14-28: Gluten challenge with 6 g/daily -10 Mean -22.5 -20 SD 51.1 Baseline: EGD with biopsy um} -30
Slide 64: IMU-856 Improved Citrulline Levels Despite Gluten Challenge
IMU-856 Improved Citrulline Levels Despite Gluten Challenge Biomarker Reflecting the Health Status and Function of Enterocytes Mean change from Baseline to Day 14 5 < Plasma citrulline levels are 7 Mean 6.1 sD 5.9 known to be related to 6 . . *, . intestinal epithelial mass and 5 . function"! 4 2, M
Slide 65: IMU-856 Improved Uptake of Essential Nutrients Vitamin B12 and Zinc
IMU-856 Improved Uptake of Actively Transported Essential Nutrients Vitamin B12 and Zinc dl Vitamin B12 Zinc Mean change from Baseline to Day 29 in vitamin B12 (pmol/L) Mean change from Baseline to Day 29 in zinc (mol/L) 80 a os 2 Loa 06 c a 04 Ew Mean 45.8 $ S sp94.4 B 02 © 20 Zo rs 5 2 g 02 - ° &
Slide 66: IMU-856 Could Become a Game Changer for the Treatment of Gastrointestinal Disorders
IMU-856 Could Become a Game Changer for the Treatment of Gastrointestinal Disorders 5 IMU-856 is poised to be a potential paradigm shift in how to treat gastrointestinal diseases. Dozens of endpoints were investigated in this proof-of-concept trial and all demonstrated that IMU-856 has a beneficial
Slide 67: Slide 67
Slide 68: Summary: Vidofludimus Calcium Is a Derisked Near-Term Opportunity
Summary: Vidofludimus Calcium Is a Derisked Near-Term Opportunity a Innovative clinical Pipeline: First-in-class oral drugs with unique modes of actions for multiple sclerosis and gastrointestinal diseases in various phases of clinical development < Relapsing MS opportunity is meaningful and de-risk
Slide 69: Thank You!
Thank You! Jessica Breu Vice President Investor Relations & Communications G Phone: +1-332-255-9819 ©& Email: ir@imux.com © Web: www.imux.com 69 | © immunic, inc. | 1an/13/2025 Immunic, Inc. 1200 Avenue of the Americas New York City, NY 10036 USA Immunic AG Lochhamer Schlag 21 82166 Grafelfing (Muni
Slide 70: Definition of Non-Active vs. Non-Relapsing SPMS
Definition of Non-Active vs. Non-Relapsing SPMS DISABILITY Non-Active SPMS 24 months — no clinical relapses Relapses || 12 months — no new MRI lesions MRI Lesions < < 12 MONTHS 12 MONTHS DISABILITY Non-Relapsing SPMS Rel 24 months — no clinical relapses elapses | MRI lesions may be present MRI Lesio
Slide 71: Comparison Patient Characteristics for CALLIPER Trial Versus Other Studies in Non-Active/Non-Relapsing SPMS
Comparison Patient Characteristics for CALLIPER Trial Versus Other Studies in the Non-Active/Non-Relapsing SPMS Population EXPAND* CALLIPER Siponimod Placebo Blinded (VidoCa + Placebo) (N=1105) (N=546) (N=267) Mean Age (Years) 48.0 48.1 Female (N,%) 669 (61%) 323 (59%) EDSS - Mean 5.4 5.4 EDSS - Med
Slide 72: Comparison Patient Characteristics for CALLIPER Trial Versus Other Studies in Non-Active/Non-Relapsing SPMS
Comparison Patient Characteristics for CALLIPER Trial Versus Other Studies in the Non-Active/Non-Relapsing SPMS Population HERCULES 3* CALLIPER Tolebrutinib Placebo Blinded (VidoCa + Placebo) (N=754) (N=377) (N=267) Mean Age (Years) 48.9 48.9 Female (N,%) 454 (60.2%) 242 (64.2%) EDSS - Mean 5.49 5.5
Slide 73: Comparison Patient Characteristics for CALLIPER Trial Versus Other Studies in the PPMS Population
Comparison Patient Characteristics for CALLIPER Trial Versus Other Studies in the PPMS Population oO RIO* CALLIPER Ocrelizimab Placebo Blinded (VidoCa + Placebo) (N=488) (N=244) (N=152) Mean Age (Years) 44.7 44.4 Female (N,%) 237 (48.6%) 124 (50.8%) EDSS - Mean 4.7 4.7 EDSS - Median 45 45 Gd+ Lesion